Friday, December 21, 2012

2012 New Drug Approvals
From Medscape Oncology
Cancer Beats All Other Fields for 2012 New Drug Approvals
1. Axitinib (Inlyta, Pfizer)
Drug monograph on Medscape Reference

FDA Approves Axitinib for Advanced Renal Cell Cancer
Medscape News, January 30, 2012
2. Vismodegib (Erivedge, Genentech)
Drug monograph on Medscape Reference

FDA Approves Vismodegib for Advanced Basal Cell Carcinoma
Medscape News, January 30, 2012
3. Pertuzumab (Perjeta, Roche)
Drug monograph on Medscape Reference

Pertuzumab Approved for HER2 Breast Cancer
Medscape News, June 11, 2012
4. Carfilzomib (Kyprolis, Onyx Pharmaceuticals)
Drug monograph on Medscape Reference

Carfilzomib Receives FDA Nod for Multiple Myeloma
Medscape News, July 20, 2012
5. Ziv-aflibercept (Zaltrap)
Drug monograph on Medscape Reference

Aflibercept Approved for Colorectal Cancer in the US
Medscape News, August 3, 2012
6. Enzalutamide (Xtandi, Astellas/Medivation)
Drug monograph on Medscape Reference

Enzalutamide Gets FDA Nod for Late-Stage Prostate Cancer
Medscape News, August 31, 2012
7. Bosutinib (Bosulif, Pfizer)
Drug monograph on Medscape Reference

A 4th Option for CML: FDA Grants Approval for Bosutinib
Medscape News, September 4, 2012
8. Regorafenib (Stivarga, Bayer)
Drug monograph on Medscape Reference

FDA Approves Regorafenib for Metastatic Colorectal Cancer
Medscape News, September 27, 2012
9. Omacetaxine mepesuccinate (Synribo, Teva Pharmaceuticals)
Drug monograph on Medscape Reference

FDA Approves New Drug for Chronic Myelogenous Leukemia
Medscape News, October 26, 2012
10. Cabozantinib (Cometriq, Exelixis)
Drug monograph on Medscape Reference

FDA Approves Cabozantinib for Medullary Thyroid Cancer
Medscape News, November 29, 2012
11. Ponatinib (lclusig, Ariad)
Drug monograph on Medscape Reference

FDA Approves Ponatinib for Rare Leukemias
Medscape News, December 14, 2012

Other Approvals
The FDA approved another 3 agents for use in cancer patients this year, either for supportive care or for imaging.


1. Glucarpidase (Voraxaze, BTG International)
Drug monograph on Medscape Reference

FDA Approves Glucarpidase to Reduce Toxic Methotrexate Levels
Medscape News, January 17, 2012

2. Tbo-filgrastim (TevaGrastim, Teva Pharma) - a biosimilar to Neupogen, Amgen
Drug monograph on Medscape Reference

FDA Approves Tbo-Filgrastim for Neutropenia
Medscape News, August 29, 2012

3. FDA Approves PET Imaging Agent for Prostate Cancer
Medscape News, September 12, 2012
Post a Comment